Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bolt Biotherapeutics
Redwood City, California, United States
- Ownership
- Private
- Employees
- ~52
- Development stage
- Other
01
Overview
Bolt Biotherapeutics is conducting a Phase 1 trial for BDC-3042, a first-in-class Dectin-2 agonist antibody that repolarizes immune cells to destroy tumors. The Boltbody™ ISAC platform has generated multiple product candidates, some in collaboration, targeting tumor antigens and leveraging innate and adaptive immune responses[1][2][3]. Most available data is early stage with limited clinical results disclosed.
- Therapeutic areas
- Oncology
- Modalities
- AntibodyAntibody-drug conjugate
- Industry
- Biotech
02
Partnerships
Toray Industries (collaboration)Genmab (collaboration)Innovent Biologics (collaboration)Stanford University (license agreement)
Beyond the preview
Go deeper on Bolt Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bolt Biotherapeutics.